TELA Bio
TELA | NASDAQ
$0.76
-$0.06 (-7.33%)
At close: Nov 16, 2026, 4:00 PM ET
$0.76
$0.00 (+0.21%)
After-hours:
Nov 16, 2026, 7:30 PM ET
TELA Bio Company Profile
Company profile explainedCompany Profile
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Heather C. Getz | CEO, Principal Financial Officer & Director |
| Paul Talmo | Chief Technology Officer |
| D. Taylor Ocasio | General Counsel & Corporate Secretary |
| Gregory A. Firestone | Chief Business Officer |
| Howard N. Langstein | Chief Medical Officer |
| Jeffrey Blizard | President |
| Jennifer Lou Armstrong | Senior Vice President of Human Resources |
| Jim Hagen | Senior VP of Strategic Commercial Operations & Marketing |
| Louisa Smith | Investor Relations Contact Officer |
| Megan Smeykal | Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer |
| Michael Leonard | Senior Vice President of Technical Operations |
| Roberto E. Cuca | CFO, Corporate Secretary & COO |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | 4 | Filing |
| Oct 19, 2026 | 4 | Filing |
| Oct 08, 2026 | 8-K | Current Report |
| Oct 06, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 8-K | Current Report |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 4 | Filing |
| Sep 14, 2026 | DEF 14A | Filing |
TELA Bio
| Country | United States |
| IPO Date | Nov 7, 2019 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 218 |
| CEO | Heather Getz |
Contact Details
1 Great Valley Parkway Malvern,
Pennsylvania 19355 United States
Stock Details
| Ticker Symbol | TELA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001561921 |
| CUSIP Number | 872381108 |
| ISIN Number | US8723811084 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove TELA